Canventol inhibits HIV-1 replication by a Tat-induced TAR-independent mechanism

Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology

Volumn 12, Issue 2, 1996, Pages 120-127

  Biswas, Debajit K ^a,c   Tius, Marcus A ^b   Zhuo, Jincong ^b   Pardee, Arthur B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF HAWAII   (United States)

^c Div of Cellular Molecular Biology   (United States)

Author keywords

Canventol; HIV 1 transcription; inhibitor of TNF ; NF B activation

Indexed keywords

CANVENTOL; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PRIORITY JOURNAL; PROMOTER REGION; VIRUS ACTIVATION; VIRUS GENE; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0029903063     PISSN: 10779450     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042560-199606010-00004     Document Type: Article

References (26)

1. Dayton AI, Sodroski JG, Rosen A, Goh WE, Haseltine WA. The trans-activator gene of the human T cell lymphocytic virus type III is required for replication. Cell 1986;44:941-7.
2. Rosen CA, Sodroski JG, Haseltine WA. The location of cis-acting regulatory sequences in the human T cell lymphotropic virus type III (HTLV-III/LAV) long terminal repeat. Cell 1985;41:813-23.
3. Fisher AG, Feinberg MB, Joseph SF, et al. The transactivator gene of HTLV-III is essential for virus replication. Nature 1986;320:361-71.
4. Sim IS. The human immunodeficiency virus tat protein, A target for antiviral agents. Ann NY Acad Sci 1990;616:64-72.
5. Jeang K-T, Chang Y-N, Berkhout B, Hammarskjold M-L, Rekosh D. Regulation of HIV expression: mechanism of action of Tat and Rev. AIDS 1991;5:S3-S14.
6. Cullen BR. Mechanism of action of regulatory proteins encoded by complex retroviruses. Microbiol Rev 1992;56: 375-94.
7. Biswas DK, Salas TR, Wang F, Ahlers CM, Dezube BJ, Pardee AB. A tat induced auto up regulatory loop for superactivation of the HIV-1 promoter. J Virol 1995;
8. Taylor JP, Pomerantz RJ, Raj GV, et al. Central nervous system-derived cells express a kappa B-binding activity that enhances human immunodeficiency virus type 1 transcription in vitro and facilitates tar-independent transactivation by Tat. J Virol 1994;68:3971-81.
9. Buonaguro L, Barillari G, Chang HK, et al. Effects of the human immunodeficiency virus type-1 tat protein on the expression of inflammatory cytokines. J Virol 1992;66: 7159-67.
10. Rautonen J, Routonen M, Martin NL, Wara DW. HIV type 1 tat protein induces immunoglobulin and interleukin 6 synthesis by uninfected peripheral blood mononuclear cells. AIDS Res Hum Retroviruses 1994;10:781-5.
11. Puri RK, Aggarwal BB. Human immunodeficiency virus type 1 tat gene up-regulates interleukin 4 receptors on a human B-lymphoblastoid cell line. Cancer Res 1992;52:787-90.
12. Biswas DK, Ahlers CM, Dezube BJ, Pardee AB. Cooperative inhibition of NF-κB and tat-induced super-activation of human immunodeficiency virus type 1 long terminal repeat. Proc Natl Acad Sci USA 1993;90:11044-8.
13. Popik W, Pitha PM. Role of tumor necrosis factor alpha in activation and replication of the tat-defective human immunodeficiency virus type 1. J Virol 1993;67:1094-9.
14. Nabel GJ, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987;326:711-3.
15. Vlach J, Pitha PM. Activation of human immunodeficiency virus, type 1 provirus in T cells and macrophages is associated with induction of inducer-specific NF-κB binding proteins. Virology 1992;187:63-72.
16. Hsu M-C, Dhingra U, Early JV, et al. Inhibition of HIV replication in acute and chronic infections in vitro by a tat antagonist. Science 1991;254:1799-802.
17. Biswas DK, Dezube BJ, Ahlers CM, Pardee AB. Pentoxifylline inhibits HIV-1 LTR-driven gene expression by blocking NF-κB action. J Acquir Immune Defic Syndr 1993;6:778-86.
18. Qatsha KA, Rudolph C, Marme D, Schachtele C, May WS. Gö 6976, selective inhibitor of protein kinase C is a potent antagonist of human immunodeficiency virus 1 induction from latent/low-level producing reservoir cells in vitro. Proc Natl Acad Sci USA 1993;90:4674-8.
19. Atsumasa K, Yatsunami J, Suganuma M, Okabe S, Abe S, Sasaki K, Fujiki H. Canventol inhibits tumor promotion in CD-1 mouse skin through inhibition of tumor necrosis factor a release and of protein isoprenylation. Cancer Res 1993;53: 3462-4.
20. Caputo A, Sodroski JG, Haseltine WA. Constitutive expression of HIV-1 tat protein in human Jurkat T cells using a BK virus vector. J Acquir Immune Defic Syndr 1990;3:372-9.
21. Biswas DK, Ahlers CA, Dezube BJ, Pardee AB. Pentoxifylline and other protein kinase C inhibitors down-regulate HIV-1 LTR NF-κB-induced gene expression. Mol Med 1994;1:31-43.
22. 1 transition of the cell cycle. Mol Cell Biol 1994; 14:5242-8.
23. Dignam JD, Lebovitz RM, Roeder RD. Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 1983;11: 1475-89.
24. Marshall WL, Diamond DC, Kowalski MM, Finberg RW. High level of surface CD4 prevents stable human immuno- deficiency virus infection of T cells transfectants. J Virol 1992;66:5492-9.
25. Mosman T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assay. J Immunol Methods 1983;65:55-64.
26. Poli G, Kiner A, Justement JS, Kehrl JH, Bressler P, Stanley S, Fauci SS. Tumor necrosis factor a functions in an autocrine manner in the induction of human immunodeficiency virus expression. Proc Natl Acad Sci USA 1990;87: 782-5.